Cybin Shareholders Vote on Rebrand to Helus Pharma, Eight-Member Board

Cybin Inc. (NASDAQ:HELP), doing business as Helus Pharma, asked shareholders to approve changing its corporate name to Helus Pharma Inc. and fixing the size of its board at eight directors. Both special resolutions required approval from at least two-thirds of the votes cast at the company's Annual General and Special Meeting of Shareholders.

Eric So, the company's co-founder and executive chairman, chaired the virtual meeting, hosted through Odyssey Trust Company's shareholder meeting platform. So confirmed the meeting had established quorum and was properly constituted to conduct business.

Meeting materials — the notice of meeting, management information circular, proxy form and financial statement request card — had been sent to shareholders of record as of Aug. 14, 2026, according to So. The company's financial statements for the fiscal year ended March 31, 2026, together with the auditor's report, were presented at the meeting. So said copies are available through SEDAR+ and the company's investor website.

Auditor and Board Size

Shareholders were asked to appoint Zeifmans LLP as auditor and authorize the board to set the auditor's remuneration. Greg Cavers, Helus Pharma's chief financial officer, moved the resolution, and director Paul Glavine seconded it.

The company also put forward the special resolution to set the number of directors at eight. Cavers moved that measure, and Glavine seconded it as well.

Name Change and Director Elections

The name-change resolution asked shareholders to approve renaming the corporation from Cybin Inc. to Helus Pharma Inc., or to another name the board approves and regulatory authorities accept.

Shareholders also considered electing eight director nominees, including Eric So, Michael Halstead, Paul Glavine, Theresa Firestone and Freda Lewis-Hall.

Vote totals and final results were not announced during the meeting. The company said the voting particulars would be published afterward.

The outcome will determine whether the psychedelic-drug developer formally completes its transition to the Helus Pharma identity across its corporate structure. Shareholders and market watchers will find the detailed voting results in the company's post-meeting filings.